Pilot study on the safety and feasibility of intravenous opioid agonist therapy (OAT) with Hydagelan® (hydromorphone hydrochloride) in Vienna.
This study, happening in Vienna, is exploring a new way to help people who are dependent on opioids. Opioid dependence is a serious, long-term health condition that affects both the mind and body, and can lead to other health problems. The study is testing a medication called Hydagelan, given directly into a vein (through a drip), to see if it's safe and if it can be practically used in a treatment setting. The main goal is to see if this treatment helps people use fewer illegal opioids. Researchers are also looking at whether it helps reduce the use of other drugs, improves overall health, and encourages people to stay in treatment.
Auf einen Blick
Worum geht es in dieser Studie?
This study is about finding better ways to help people who are struggling with opioid dependence. Opioid dependence is a very serious health condition where a person relies on opioids, which can be prescription pain relievers or illegal drugs like heroin. It's not just a physical problem; it affects a person's thoughts, feelings, and overall life. People living with opioid dependence often face other health issues and sadly, it can even shorten lives.
The study is testing a new form of treatment called opioid agonist therapy (OAT) using a medication called Hydagelan. This medication is given directly into a vein, like you might have a drip in a hospital. The medical team wants to find out if giving Hydagelan this way is a safe and practical option for people. They are hoping it will help people reduce how often they use illegal opioids.
Beyond just reducing illegal opioid use, the study also aims to see if this treatment helps people cut down on other drugs, improves their general health and wellbeing, and encourages them to stay in their treatment programme. This type of research, called a Phase II study, is an early step in testing new treatments to make sure they are safe and could be helpful for patients.
Wichtige Erkenntnisse
- The study is testing a new treatment called Hydagelan for opioid dependence.
- It's exploring if giving Hydagelan through a drip is safe and practical.
- A main goal is to help people reduce their use of illegal opioids.
- The study will also look at overall health improvements and treatment retention.
- It's an early-stage study, meaning more research will be needed in the future.
Wer könnte berechtigt sein?
To join this study, participants must be at least 18 years old. Both men and women are welcome to take part.
More specific details about who can join will be provided by the study team. For example, they will need to check your medical history to make sure the treatment is suitable and safe for you.
It's important to discuss your full medical background and any medications you are currently taking with the study doctor to see if you are a good fit for this research.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Are you a man or a woman?
- Do you have opioid dependence?
- Are you willing to receive medication through an intravenous drip?
- Can you commit to regular clinic visits for treatment and check-ups?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you would first have a full health check-up to make sure the treatment is right for you. The main part of the treatment involves receiving the study medication, Hydagelan, directly into a vein (like a drip). The strength of the medication will be one of three options: 50 mg/ml, 10 mg/ml, or 20 mg/ml solution. The research team will regularly check your health and how you are responding to the treatment. They will also keep track of your opioid use and any other drug use. This involves regular visits to the clinic for assessments and to receive your treatment. The total duration of the study, including how long you would receive treatment and how long they will follow up with you afterwards, would be fully explained by the study team.
Potenzielle Risiken und Vorteile
Standorte (1)
- —UnbestätigtÖsterreich
Häufige Fragen
What is opioid dependence?
Opioid dependence is a serious health condition where a person's body and mind rely on opioids, affecting their health and daily life.
What is Hydagelan?
Hydagelan is a medication being tested in this study as a treatment for opioid dependence, given through a drip.
What does 'intravenous' mean?
Intravenous means the medication is given directly into a vein, usually through a small tube or drip.
Will this study help me stop using drugs completely?
This study aims to help reduce the use of illegal opioids and improve health, but it's part of a broader treatment approach.
Kann ich die Studie jederzeit verlassen?
Yes, you have the right to leave the study at any point without it affecting your usual medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.